These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17652815)

  • 41. HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
    Reynolds JG; Geretti E; Hendriks BS; Lee H; Leonard SC; Klinz SG; Noble CO; Lücker PB; Zandstra PW; Drummond DC; Olivier KJ; Nielsen UB; Niyikiza C; Agresta SV; Wickham TJ
    Toxicol Appl Pharmacol; 2012 Jul; 262(1):1-10. PubMed ID: 22676972
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart.
    Plandé J; Platel D; Tariosse L; Robert J
    Toxicol Lett; 2006 Feb; 161(1):37-42. PubMed ID: 16129573
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Molecular pharmacology of the interaction of anthracyclines with iron.
    Xu X; Persson HL; Richardson DR
    Mol Pharmacol; 2005 Aug; 68(2):261-71. PubMed ID: 15883202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Topoisomerase 2β: a promising molecular target for primary prevention of anthracycline-induced cardiotoxicity.
    Vejpongsa P; Yeh ET
    Clin Pharmacol Ther; 2014 Jan; 95(1):45-52. PubMed ID: 24091715
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monitoring of anthracycline-induced cardiotoxicity.
    Jannazzo A; Hoffman J; Lutz M
    Ann Pharmacother; 2008 Jan; 42(1):99-104. PubMed ID: 18094345
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
    Langer SW; Jensen PB; Sehested M
    Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways.
    Pugatsch T; Abedat S; Lotan C; Beeri R
    Breast Cancer Res; 2006; 8(4):R35. PubMed ID: 16839426
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
    Goey AK; Schellens JH; Beijnen JH; Huitema AD
    Ned Tijdschr Geneeskd; 2010; 154():A1155. PubMed ID: 20619024
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anthracyclines enhance tension development in cardiac muscle by direct interaction with the contractile system.
    Bottone AE; de Beer EL; Voest EE
    J Mol Cell Cardiol; 1997 Mar; 29(3):1001-8. PubMed ID: 9152861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of cardiac troponin T levels as an indicator of doxorubicin-induced cardiotoxicity.
    Herman EH; Lipshultz SE; Rifai N; Zhang J; Papoian T; Yu ZX; Takeda K; Ferrans VJ
    Cancer Res; 1998 Jan; 58(2):195-7. PubMed ID: 9443390
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anthracyclines induce calpain-dependent titin proteolysis and necrosis in cardiomyocytes.
    Lim CC; Zuppinger C; Guo X; Kuster GM; Helmes M; Eppenberger HM; Suter TM; Liao R; Sawyer DB
    J Biol Chem; 2004 Feb; 279(9):8290-9. PubMed ID: 14676206
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sublethal doses of an anti-erbB2 antibody leads to death by apoptosis in cardiomyocytes sensitized by low prosenescent doses of epirubicin: the protective role of dexrazoxane.
    Spallarossa P; Altieri P; Pronzato P; Aloi C; Ghigliotti G; Barsotti A; Brunelli C
    J Pharmacol Exp Ther; 2010 Jan; 332(1):87-96. PubMed ID: 19841470
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk.
    Barrett-Lee PJ; Dixon JM; Farrell C; Jones A; Leonard R; Murray N; Palmieri C; Plummer CJ; Stanley A; Verrill MW
    Ann Oncol; 2009 May; 20(5):816-27. PubMed ID: 19153118
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct contribution of Rac1 expression in cardiomyocytes to anthracycline-induced cardiac injury.
    Henninger C; Pohlmann S; Ziegler V; Ohlig J; Schmitt J; Fritz G
    Biochem Pharmacol; 2019 Jun; 164():82-93. PubMed ID: 30936017
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
    Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
    Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mechanisms of the Cardiac Myocyte-Damaging Effects of Dasatinib.
    Hasinoff BB; Patel D
    Cardiovasc Toxicol; 2020 Aug; 20(4):380-389. PubMed ID: 32124237
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cardiotoxicity of Cancer Treatments: Focus on Anthracycline Cardiomyopathy.
    Nishi M; Wang PY; Hwang PM
    Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2648-2660. PubMed ID: 34587760
    [TBL] [Abstract][Full Text] [Related]  

  • 58. DNA damage is an early event in doxorubicin-induced cardiac myocyte death.
    L'Ecuyer T; Sanjeev S; Thomas R; Novak R; Das L; Campbell W; Heide RV
    Am J Physiol Heart Circ Physiol; 2006 Sep; 291(3):H1273-80. PubMed ID: 16565313
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of iron and iron chelators in anthracycline cardiotoxicity.
    Hershko C; Link G; Tzahor M; Pinson A
    Leuk Lymphoma; 1993 Oct; 11(3-4):207-14. PubMed ID: 8260895
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mitochondria death/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies.
    Montaigne D; Hurt C; Neviere R
    Biochem Res Int; 2012; 2012():951539. PubMed ID: 22482055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.